Healthcare Industry News: Roche
News Release - June 5, 2012
Former Pfizer Worldwide Business Development Director Joins Australian Drug Development Company AgenixMELBOURNE, Australia--(Healthcare Sales & Marketing Network)--Australian-based drug and development company Agenix Limited (AGX.AX) today announced the appointment of Dr Paul Resnick as business advisor. Dr Resnick will initially focus on the Company’s revolutionary blood clot diagnostic ThromboView®.
Dr Resnick is the former Vice President of Business Development at privately held US-based biotechnology business Intellikine Inc where he played a key role in securing a $489 million program licensing deal and the subsequent sale of the business in December 2011 to Japan’s Takeda Pharmaceutical Co for $310 million.
Before joining Intellikine, Dr Resnick was Senior Director of Worldwide Business Development at Pfizer Inc (PFE). He previously held roles at Rinat Neuroscience, InterMune, Roche Pharmaceuticals and practiced medicine. At Rinat Neuroscience, he played a key role in its acquisition by Pfizer Inc.
Agenix Chairman and Chief Executive Officer Nicholas Weston said, "Paul adds significant depth and experience to our team and will provide strategic guidance and negotiation support as we progress our promising commercial and clinical programs.”
“Agenix is continuously engaged with potential strategic corporate partners in multiple geographies. Paul will help us manage this important process in a timely and efficient manner to achieve the best possible results that create shareholder value.”
Dr Resnick said “I see significant unrecognized potential and value in Agenix and the exciting assets it has developed. There is a compelling proposition in ThromboView's strong clinical safety and efficacy profile and its potential value in a range of clinical applications.”
ThromboView® is a registered trademark of Agen Biomedical Limited, a wholly owned subsidiary of Agenix Limited.
Agenix is a public, clinical-stage company focused on the discovery and development of innovative monoclonal antibody blood clot diagnostics, and small molecule drugs for the treatment of hepatitis B and other serious diseases. Agenix’s most advanced diagnostic candidate, ThromboView®, a novel radio-labelled monoclonal antibody imaging agent, has completed two Phase 2 clinical trials, and is ideal to diagnose patients indicated for suspected acute pulmonary embolism (PE), with a positive D-dimer blood test or moderate to high pre-test probability of PE, as a replacement diagnostic test for patients with suspected PE where V/Q scans are a first line choice and are unlikely to deliver a diagnostic result, as a confirmatory diagnostic where CT is used as a first-line diagnostic test, the scan result is negative and the clinical probability of disease is high or moderate and as a replacement diagnostic where CTPA is an inappropriate choice based on radiation exposure, renal impairment or contrast allergy. Agenix is also developing AGX 1009, a next-generation reverse transcriptase inhibitor (NtRTI) prodrug of tenofovir, for which a CTA is planned to be filed with the Chinese FDA in the second half of 2012 and for which the Company plans to advance into Phase 1 in the second half of 2013. Agenix owns all the patent rights to both ThromboView® and AGX 1009. In August 2010, Agenix entered into a collaborative partnership with the Institute of Medicinal Biotechnology of the Chinese Academy of Medical Sciences, part of the Ministry of Health to purchase AGX 1009 and preclinical work is being conducted in Beijing, China by the Institute of Pharmacology and Toxicology of the Academy of Military Medical Sciences. Agenix has taken successfully from laboratory to global commercialisation then commercial exit more than 20 products over four technology platforms since listing on the Australian Securities Exchange in 1987.
Source: Agenix Limited
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.